We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Galectin Therapeutics

News List

Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover biospace
December 21, 2017
Galectin Therapeutics (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it entered into a $10 million unsecured line of credit facility with stockholder and new director Richard E. Uihlein.
Galectin Therapeutics' share value plummets by half after NASH drug failure pharmafile
December 07, 2017
Galectin Therapeutics has seen its share value almost halve after its revealed that GR-MD-02, its experimental treatment for non-alcoholic steatohepatitis (NASH) cirrhosis, had missed its primary endpoint in a Phase 2b trial.